Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Bullinger

Showing results (231-240 of 385) with videos related to

Pageof 39
Sort By:
Blood|April 24, 2019
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemiaAnnika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, et al.
European Journal of Heart Failure|November 27, 2024
New cardiovascular biomarkers in patients with advanced cancer - A prospective study comparing MR-proADM, MR-proANP, copeptin, high-sensitivity troponin T and NT-proBNPMarkus S Anker, Laura C Lück, Muhammad Shahzeb Khan, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|December 24, 2010
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entityErdogan Taskesen, Lars Bullinger, Andrea Corbacioglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study groupVerena I Gaidzik, Lars Bullinger, Richard F Schlenk, et al.
Neurosurgery|October 31, 2015
Low-grade Glioma Surgery in Intraoperative Magnetic Resonance Imaging: Results of a Multicenter Retrospective Assessment of the German Study Group for Intraoperative Magnetic Resonance ImagingJan Coburger, Andreas Merkel, Moritz Scherer, et al.
Leukemia|October 3, 2018
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careHartmut Döhner, Anna Dolnik, Lin Tang, et al.
Blood|June 20, 2020
Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cellsSimon Raffel, Daniel Klimmeck, Mattia Falcone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
Cytotherapy|November 12, 2024
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disordersDimitrios Mougiakakos, Ranjita Sengupta, Ralf Gold, et al.
Pageof 39

Showing results (231-240 of 385) with videos related to

Sort By:
Pageof 39
Blood|April 24, 2019
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemiaAnnika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, et al.
European Journal of Heart Failure|November 27, 2024
New cardiovascular biomarkers in patients with advanced cancer - A prospective study comparing MR-proADM, MR-proANP, copeptin, high-sensitivity troponin T and NT-proBNPMarkus S Anker, Laura C Lück, Muhammad Shahzeb Khan, et al.
Journal for Immunotherapy of Cancer|May 17, 2022
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCLKai Rejeski, Ariel Perez, Gloria Iacoboni, et al.
Blood|December 24, 2010
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entityErdogan Taskesen, Lars Bullinger, Andrea Corbacioglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study groupVerena I Gaidzik, Lars Bullinger, Richard F Schlenk, et al.
Neurosurgery|October 31, 2015
Low-grade Glioma Surgery in Intraoperative Magnetic Resonance Imaging: Results of a Multicenter Retrospective Assessment of the German Study Group for Intraoperative Magnetic Resonance ImagingJan Coburger, Andreas Merkel, Moritz Scherer, et al.
Leukemia|October 3, 2018
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional careHartmut Döhner, Anna Dolnik, Lin Tang, et al.
Blood|June 20, 2020
Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cellsSimon Raffel, Daniel Klimmeck, Mattia Falcone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2025
Spatial tumor immune microenvironment as a prognostic and predictive biomarker in anti-EGFR-based maintenance for RAS wt metastatic CRC - the PanaMa (AIO KRK0212) trialAlexej Ballhausen, Susanna Swoboda, David Horst, et al.
Cytotherapy|November 12, 2024
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disordersDimitrios Mougiakakos, Ranjita Sengupta, Ralf Gold, et al.
Pageof 39